Related Experiment Video
Updated: Jul 16, 2025
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Targeting SDCBP2 in acute myeloid leukemia
Yan Du1, Lan-Lan Li2, Feihu Chen3
1Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230001, China; The Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of Traditional Chinese Medicine, Hefei, Anhui 230001, China; School of Pharmacy, Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, Anhui Medical University, Hefei 230022, China; Institute for Liver Disease of Anhui Medical University, Anhui Medical University, Hefei 230022, China.
This study identifies SDCBP2 as a target gene of E2A in acute myeloid leukemia (AML). Inhibiting SDCBP2 shows promise for delaying AML progression and offers a potential new therapeutic strategy.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Acute myeloid leukemia (AML) is a complex blood cancer with poor outcomes.
- Previous research suggested E2A as a potential therapeutic target in AML, but the mechanism remained unknown.
Purpose of the Study:
- To elucidate the mechanism by which E2A influences AML.
- To identify and validate SDCBP2 as a potential therapeutic target in AML.
Main Methods:
- RNA-sequencing (RNA-seq) and Chromatin Immunoprecipitation sequencing (ChIP-seq) were used for screening.
- Co-immunoprecipitation (Co-IP) assays confirmed protein interactions.
- AML cell lines and patient samples were analyzed for gene expression.
- In vivo studies utilized a human xenograft mouse leukemia model.
Main Results:
- SDCBP2 was identified as a target gene of E2A.
- Both E2A and SDCBP2 expression levels were elevated in AML.
- Downregulation of SDCBP2 inhibited AML cell proliferation and promoted differentiation.
- Inhibition of SDCBP2 delayed leukemia progression in a mouse model.
Conclusions:
- SDCBP2 is confirmed as a target gene of E2A in AML.
- SDCBP2 represents a promising therapeutic target for AML treatment.
